HC Wainwright & Co. Maintains Buy on Inhibikase Therapeutics, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Inhibikase Therapeutics (NASDAQ:IKT) but has lowered the price target from $27 to $23.
May 21, 2024 | 10:45 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained its Buy rating on Inhibikase Therapeutics but has lowered the price target from $27 to $23.
The Buy rating suggests continued confidence in the stock, but the lowered price target indicates a more cautious outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100